Protagenic Therapeutics, Inc.\new: directors' dealings · United States · SEC (Form 4)

About Protagenic Therapeutics, Inc.\new

Protagenic Therapeutics, Inc. (ticker: PTIX) is a United States-based biotechnology company listed on the Nasdaq Capital Market in the NYSE/NASDAQ universe, with its principal executive office in New York City at 149 Fifth Avenue, Suite 500. For investors, the company should be viewed as a highly specialized neuroactive drug developer focused on peptide biology and, more specifically, on the TCAP (teneurin C-terminal associated peptide) pathway. Its core investment case is therefore scientific and clinical in nature: value creation depends less on current revenues than on the ability to advance a differentiated pipeline, secure funding, and translate a novel mechanism into meaningful human data. Protagenic’s corporate history has been eventful. SEC filings indicate that the company traces its roots to a Delaware corporation organized in 2004, and over time it has gone through multiple restructurings and strategic pivots. In recent filings, the company is described as a Delaware corporation with a Canadian subsidiary, Protagenic Therapeutics Canada (2006) Inc., although the strategic center of gravity remains the United States. The most important recent corporate development was the March 2026 announcement that Protagenic completed the separation of Phytanix, strengthened its balance sheet, and repositioned the business around PT00114. Shortly after that, in April 2026, the company appointed Bill Nichols Jr. as President to accelerate the development of PT00114. From an operating perspective, Protagenic remains pre-commercial. It does not appear to have an approved marketed product, and its pipeline is still concentrated in early-stage development. PT00114 is the lead program and is described by the company as a first-in-class investigational compound targeting the TCAP pathway for stress-related disorders, including treatment-resistant depression, anxiety, PTSD, and related conditions. The company also references follow-on compounds in the TCAP family. This makes PTIX a niche, mechanism-driven biotech with potentially attractive upside if its scientific thesis is validated, but also with substantial binary risk typical of small-cap biotech companies. Competitive positioning is best understood in relative terms. PTIX is not a commercial scale pharmaceutical company; it is a clinical-stage developer competing indirectly with much larger pharmaceutical groups, as well as other neuroscience and psychiatry biotechs, in a therapeutic area with high unmet need and historically challenging clinical success rates. Its differentiation lies in the novelty of the TCAP pathway and the company’s claim that PT00114 may modulate stress-related biology without interfering with normal brain function. Geographically, the company’s footprint is limited and centered in New York, with any broader presence tied to research or corporate development rather than sales infrastructure. Recent headlines have therefore been dominated by capital structure, corporate reset, and leadership changes rather than product revenues. For French, Belgian, and Swiss investors, Protagenic should be framed as a speculative U.S. biotech story: no commercial maturity yet, but a focused pipeline, a distinct scientific angle, and a recent strategic reorganization that could either de-risk the story or underscore how dependent it remains on clinical execution and financing.